Maxcyte, INC DEF 14A proxy statements

MaxCyte, Inc. is soliciting stockholder votes for its 2025 Annual Meeting, proposing the election of three Class I directors, an increase in its equity incentive plan shares, and the cancellation of its AIM trading admission.

MaxCyte is asking stockholders to approve an amendment to its equity incentive plan and to delist from the AIM market of the London Stock Exchange.

MaxCyte is asking stockholders to approve an amendment to its 2022 Equity Incentive Plan to increase the number of shares available for issuance by 2,300,000 at the Annual Meeting on June 11, 2024.